Digoxin and Second primary malignancy - a phase IV clinical study of FDA data

Summary:

Second primary malignancy is reported as a side effect among people who take Digoxin (digoxin), especially for people who are male, 60+ old, also take Pantoprazole, and have Carcinoid tumor.

The phase IV clinical study analyzes which people have Second primary malignancy when taking Digoxin. It is created by eHealthMe based on reports of 92,292 people who have side effects when taking Digoxin from the FDA, and is updated regularly.

What is Digoxin?

Digoxin has active ingredients of digoxin. It is often used in atrial fibrillation/flutter. eHealthMe is studying from 93,739 Digoxin users. Check the latest studies of Digoxin.

What is Second primary malignancy?

Second primary malignancy (after getting cure a cancer, a new cancer development) is found to be associated with 542 drugs and 464 conditions by eHealthMe. Check the latest studies of Second primary malignancy.

On Apr, 25, 2026

92,292 people reported to have side effects when taking Digoxin.
Among them, 14 people (0.02%) have Second primary malignancy.

Could Digoxin cause Second primary malignancy?

Among these 14 people:

What is the gender of people who have Second primary malignancy when taking Digoxin? *

female: 30.77 %
male: 69.23 %

What is the age of people who have Second primary malignancy when taking Digoxin? *

What are other drugs people take besides Digoxin? *

What are other side effects people have besides Second primary malignancy? *

Weight Decreased: 10 people, 71.43%
High Blood Pressure: 7 people, 50.00%
Sepsis (a severe blood infection that can lead to organ failure and death): 7 people, 50.00%
Pain: 6 people, 42.86%
Fall: 6 people, 42.86%
Thrombocytopenia (decrease of platelets in blood): 6 people, 42.86%
Malaise (a feeling of general discomfort or uneasiness): 6 people, 42.86%
Metastases To Bone (cancer spreads to bone): 5 people, 35.71%
Death: 5 people, 35.71%
Haematuria (presence of blood in urine): 5 people, 35.71%

What are the existing conditions these people have? *

Carcinoid Tumor: 6 people, 42.86%
Neuroendocrine Tumor: 4 people, 28.57%
Multiple Myeloma (cancer of the plasma cells): 2 people, 14.29%
Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 2 people, 14.29%
Breast Cancer Metastatic: 2 people, 14.29%
Renal Cell Carcinoma (a kidney cancer): 1 person, 7.14%
Osteoporosis (bones weak and more likely to break): 1 person, 7.14%
Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 1 person, 7.14%
Joint Pain: 1 person, 7.14%
Inflammation: 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Digoxin and have Second primary malignancy?

- Check whether Second primary malignancy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Digoxin:

Digoxin (93,739 reports)

Browse all side effects of Digoxin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Second primary malignancy:

Second primary malignancy (542 drugs)

Browse all the conditions that are associated with Second primary malignancy:

Second primary malignancy (464 conditions)

Related publications that referenced our studies

Guru SR, Suresh A, Padmanabhan S, Reddy A, "A Rare Case of Digoxin Associated Gingival Overgrowth", Journal of clinical and diagnostic research: JCDR, 2017 Jan .
Lai SW, Lin CL, Liao KF, "Digoxin use may increase the relative risk of acute pancreatitis: a population-based case–control study in Taiwan", International journal of cardiology, 2015 Feb .
Guru SR, Suresh A, Padmanabhan S, Reddy A, "A Rare Case of Digoxin Associated Gingival Overgrowth", Journal of clinical and diagnostic research: JCDR, 2017 Jan .
Lai SW, Lin CL, Liao KF, "Digoxin use may increase the relative risk of acute pancreatitis: a population-based case–control study in Taiwan", International journal of cardiology, 2015 Feb .

How the study uses the data?

The study uses data from the FDA. It is based on digoxin (the active ingredients of Digoxin) and Digoxin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.